5-(6-amino-purin-9-ylmethyl)-3-cyclopentylmethoxy-benzene-1,2-diol | 1192852-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 5-(6-amino-purin-9-ylmethyl)-3-cyclopentylmethoxy-benzene-1,2-diol
• 英文别名: 5-[(6-Aminopurin-9-yl)methyl]-3-(cyclopentylmethoxy)benzene-1,2-diol
• CAS: 1192852-51-9
• 化学式: C₁₈H₂₁N₅O₃
• 分子量: 355.396
• InChiKey: OEAFYMXSWRXPJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 甲酸 作用下， 反应 24.0h， 以93%的产率得到5-(6-amino-purin-9-ylmethyl)-3-cyclopentylmethoxy-benzene-1,2-diol
  参考文献：
  名称：

  A new structural class of S-adenosylhomocysteine hydrolase inhibitors

  摘要：

  Effective inhibitors of S-adenosylhomocysteine hydrolase hold promise towards becoming useful therapeutic agents. Since most efforts have focused on the development of nucleoside analog inhibitors, issues regarding bioavailability and selectivity have been major challenges. Considering the marine sponge metabolite ilimaquinone was found to be a competitive inhibitor of S-adenosylhomocysteine hydrolase, new opportunities for developing selective new inhibitors of this enzyme have become available. Based on the activities of various hybrid analogs, SAR studies, pharmacophore modeling, and computer docking studies have lead to a predictive understanding of ilimaquinone's S-adenosylhomocysteine hydrolase inhibitory activities. These studies have allowed for the design and preparation of simplified structural variants possessing new furanoside bioisosteres with 100-fold greater inhibitory activities than that of the natural product. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2009.07.061

文献信息

• A new structural class of S-adenosylhomocysteine hydrolase inhibitors
  作者：Byung Gyu Kim、Tae Gyu Chun、Hee-Yoon Lee、Marc L. Snapper

  DOI：10.1016/j.bmc.2009.07.061

  日期：2009.9

  Effective inhibitors of S-adenosylhomocysteine hydrolase hold promise towards becoming useful therapeutic agents. Since most efforts have focused on the development of nucleoside analog inhibitors, issues regarding bioavailability and selectivity have been major challenges. Considering the marine sponge metabolite ilimaquinone was found to be a competitive inhibitor of S-adenosylhomocysteine hydrolase, new opportunities for developing selective new inhibitors of this enzyme have become available. Based on the activities of various hybrid analogs, SAR studies, pharmacophore modeling, and computer docking studies have lead to a predictive understanding of ilimaquinone's S-adenosylhomocysteine hydrolase inhibitory activities. These studies have allowed for the design and preparation of simplified structural variants possessing new furanoside bioisosteres with 100-fold greater inhibitory activities than that of the natural product. (C) 2009 Published by Elsevier Ltd.